Skip to main content
Lipocine Inc. logo

Lipocine Inc. — Investor Relations & Filings

Ticker · LPCN ISIN · US53630X1046 LEI · 549300RXPEQXOJXVBI10 US Manufacturing
Open in API
Filings indexed 788 across all filing types
Latest filing 2013-11-04 Capital/Financing Update
Country US United States of America
Listing US LPCN

About Lipocine Inc.

https://www.lipocine.com/

Lipocine Inc. is a clinical-stage biopharmaceutical company that develops treatments for metabolic, endocrine, and central nervous system disorders. The company leverages its proprietary Lip'ral drug delivery technology to enhance the oral absorption of water-insoluble drugs, aiming to improve patient compliance and therapeutic outcomes. Its portfolio includes TLANDO®, an FDA-approved oral testosterone replacement therapy. Lipocine's development pipeline features candidates for conditions such as non-alcoholic steatohepatitis (NASH), postpartum depression, obesity, and prevention of preterm birth. The company's strategy often involves using the 505(b)(2) regulatory pathway to develop improved formulations of established drugs.

Recent filings

Filing Released Lang Actions
FORM S-1
Capital/Financing Update Classification · 100% confidence The document is a Form S-1 Registration Statement filed with the U.S. Securities and Exchange Commission. It includes detailed information about the company, the securities being offered, risk factors, use of proceeds, management discussion, and financial statements. Form S-1 is a registration statement used for initial public offerings or other securities offerings and is not an annual report, earnings release, or other types of filings listed. The document is a comprehensive registration statement for a securities offering, which aligns with the Capital/Financing Update category, as it relates to company fundraising and capital structure changes.
2013-11-04 English
8-A12G
Regulatory Filings Classification · 95% confidence The document is a Form 8-A filed with the SEC, which is used for the registration of certain classes of securities pursuant to Section 12(b) or 12(g) of the Securities Exchange Act of 1934. It includes details about the registrant's securities to be registered and references prior filings such as Form S-1 and 8-K exhibits. The document is not a financial report, earnings release, or management discussion but a regulatory filing related to securities registration. Given the nature and content, it fits best under Regulatory Filings (RNS). The document length is 3082 characters, which is relatively short and consistent with a regulatory filing rather than a full report.
2013-10-21 English
S-8
Regulatory Filings Classification · 95% confidence The document is a Form S-8 Registration Statement filed with the SEC, which is used for registering securities to be offered under employee benefit plans such as equity incentive plans. It includes detailed information about the securities to be registered, the plan under which they are offered, indemnification provisions, and exhibits related to the plan and corporate governance documents. It is not a financial report, earnings release, or management discussion, but a registration statement related to equity compensation plans. This type of filing is a regulatory filing related to securities registration and does not fit into other specific categories like Annual Report, Earnings Release, or Proxy Statement. Therefore, it should be classified as Regulatory Filings (RNS). The document length is substantial (15,000 characters), and it is not merely an announcement or certification, so it is not RPA or a certification filing.
2013-10-11 English
FILED PURSUANT TO RULE 424(B)(3)
Capital/Financing Update Classification · 95% confidence The document is a prospectus filed pursuant to Rule 424(b)(3) related to the sale of shares by selling stockholders. It includes detailed information about the company, risk factors, management discussion, business description, and financial statements index. The document is a registration prospectus for a secondary offering of shares previously issued in a private placement. It is not an earnings release, annual report, or any other financial report but a capital markets document related to share disposition. This fits the definition of a Capital/Financing Update (CAP) as it provides updates on company fundraising and capital structure changes through the sale of shares by selling stockholders. The document length is substantial (15,000 characters), indicating it is the full prospectus, not just an announcement. Therefore, the correct classification is CAP with high confidence.
2013-09-27 English
Regulatory Filings 2013
Regulatory Filings
2013-09-27 English
AMENDMENT NO. 1 TO FORM S-1
Capital/Financing Update Classification · 100% confidence The document is titled 'Amendment No. 1 to Form S-1' and is a registration statement filed with the U.S. Securities and Exchange Commission under the Securities Act of 1933. It includes detailed information about the company, Lipocine Inc., its business, risk factors, management, and selling stockholders. The Form S-1 is a registration statement used for initial public offerings or other securities offerings. This document is not an annual report, earnings release, or any other financial report but rather a capital markets filing related to securities registration and offering. Therefore, it fits best under the category of Capital/Financing Update (CAP), which covers updates on company fundraising and financing activities, including registration statements for securities offerings.
2013-09-25 English

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.